ArticleFrontiers in pharmacology2024

Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in the Chinese healthcare system.

Wenwang Lang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.